← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBiologicstaleAbbViePhase 2

MIRV; IMGN853 (mirvetuximab soravtansine, mirvetuximab soravtansine (MIRV; IMGN853))

Ovarian Cancer; Fallopian Tube · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 100%임상시험 27상태 RECRUITING
ADCBiologicstaleLepu Medical Technology (Beijin…Phase 3

Becotatug Vedotin (Becotatug Vedotin)

Nasopharyngeal Carcinoma (NPC) · Adenoid Cystic Carcinoma

#AdenoidCysticCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 26상태 RECRUITING
ADCBiologicstaleSeagenPreclinical

brentuximab vedotin (Adcetris, Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine)

Anti-CD30; Brentuximab · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 26상태 ACTIVE
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Drug: Disitamab Vedotin)

Upper Urinary Tract Urothelial Carcinoma · Upper Urinary Tract Urothelial Carcinoma

#UpperUrinaryTractUrothelialCarci#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 26상태 RECRUITING
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Phesgo (Phesgo)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 50%임상시험 26상태 RECRUITING
ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 80%임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

POLA-R-CHP (POLA-R-CHP)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 95%임상시험 25상태 RECRUITING
ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

ARV-471 (ARV-471)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 24상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD2936 (AZD2936)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 24상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

PLX3397 (PLX3397)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 24상태 RECRUITING
ADCBiologicstaleSpectrum Pharmaceuticals, IncPhase 1

Poziotinib (Poziotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 30%임상시험 24상태 DISCONTINUED
ADCBiologicstaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 44%임상시험 24상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

U3-1402 (U3-1402)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 ACTIVE
ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 27.8%임상시험 23상태 ACTIVE

19 / 54 페이지

← 이전다음 →